Tevogen Bio Holdings (TVGN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Tevogen Bio Holdings (TVGN) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tevogen Bio Holdings's market cap?
Tevogen Bio Holdings (TVGN) has a market capitalization of approximately
How profitable is Tevogen Bio Holdings?
Tevogen Bio Holdings runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Tevogen Bio Holdings pay a dividend?
Tevogen Bio Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Tevogen Bio Holdings financially healthy?
Tevogen Bio Holdings carries a debt-to-equity ratio of -0.31x and a current ratio of 0.29x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tevogen Bio Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tevogen Bio Holdings (TVGN) the key facts are: market cap
Track Tevogen Bio Holdings's full fundamentals live
Get Tevogen Bio Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.